Thursday 22nd July 2021
Are you reading this from a touchscreen device? Using touchscreen technology is something many of us do every day, without even thinking about it. But what happens to the people who have conditions that make touchscreens tough?
Friday 16th July 2021
Systemic sclerosis-associated pulmonary arterial hypertension (SSC-PAH) occurs when fibrosis causes the walls of the pulmonary arteries to thicken, raising their blood pressure and placing additional strain upon the heart. The early signs of SSc-PAH include persistent breathlessness, that may be so mild at first that you hardly notice it. If this sounds familiar, tell your doctor.
Thursday 8th July 2021
“We are limited by current assessment tools such as the skin score, which is limited by subjectivity, as well as the time needed for training and standardisation. We need to make sure that new treatments are evaluated in the best and most robust way so that we can make more progress and discontinue approaches that do not work.” Prof. Chris Denton
Thursday 10th June 2021
A coalition of charities, including SRUK has written an open letter to employers, calling for them to put protective measures in place for staff who may have reduced protection from the COVID-19 vaccine.
Friday 7th May 2021
SRUK is pioneering ‘The Raynaud’s ResearchApp,’ that aims to help identify Raynaud’s patients at risk of developing scleroderma, with a view to achieving earlier diagnosis and improved outcomes. The technology also enables users to record their experiences of Raynaud’s symptoms and learn more about potential triggers. The App has recently been piloted in a clinical trial.
Friday 16th April 2021
What is the link between our genetic code and developing scleroderma? Researchers from Spain have recently studied genetic alterations and established a connection with the pathways that dictate the clinical features of scleroderma. The study is significant because increasing our understanding of the genetic pathway could be a faster route towards identifying effective new therapies for this complex condition.
Thursday 1st April 2021
SRUK is working with our partners at the Association of Medical Research Charities via their new Open Research Platform, to revolutionise the publishing process for our researchers. This will enable SRUK-funded research groups to publish their work in a streamlined and cost-effective way, with the ultimate goal of translating new knowledge into effective treatments for people living with scleroderma.
Friday 19th March 2021
Clinical trials are the only way to ensure that new treatments are effective. But how exactly does the process work? FInd out why 'outcome measures’ and ‘endpoints’ are crucial, and how SRUK funding is playing a key role in improving the measures used in treatments for scleroderma.
Thursday 25th February 2021
A new study from the UK has identified a possible connection between metabolism and fibrosis in people with scleroderma, with the potential to open up new treatment avenues in the future.
Monday 18th January 2021
Would you like to have your say on whether a treatment is made available for progressive fibrosing interstitial lung disease (PF-ILD)?
